Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 8.213
Filtrer
1.
Int J Mol Sci ; 25(13)2024 Jun 26.
Article de Anglais | MEDLINE | ID: mdl-39000070

RÉSUMÉ

Severe haematological diseases and lymphoid malignancies require bone marrow (BM)-suppressive treatments. Knowledge regarding the impact of BM-suppressive treatments on children's memory T cells is very limited. Memory T cells play a crucial role in defending against herpesviruses, which is particularly relevant in paediatric cancer care. We studied 53 children in total; 34 with cancer and 2 with severe haematological disorders, with some receiving BM-suppressive treatment with or without allogeneic-haematopoietic stem cell transplantation (allo-HSCT), alongside 17 healthy controls. We focused on peripheral blood proportions of memory T-cell subsets using flow cytometry and analysed cytokine-secreting T cells with a four-parameter FluoroSpot assay in response to T-cell mitogen and varicella zoster virus (VZV) peptides. Patients on BM-suppressive treatment showed increased clusters of differentiation (CD)4+ and CD8+ effector memory (TEM)/terminally differentiated effector (TEFF) T cells compared to the healthy controls. They also exhibited, amongst other things, when compared to the healthy controls, a reduced total number of cytokine-secreting cells, by means of interferon (IFN)-γ, interleukin (IL)-17A, IL-10, and IL-22, following mitogen activation. A diminished IFN-γ response among the children with BM-suppressive treatment was observed upon VZV-peptide stimulation, compared to the healthy children. Collectively, the findings herein indicate that the children who are undergoing or have finished BM-suppressive treatment display qualitative differences in their T-cell memory compartment, potentially increasing their susceptibility to severe viral infections and impacting their immunotherapy, which relies on the functional ability of autologous T cells.


Sujet(s)
Herpèsvirus humain de type 3 , Interféron gamma , Humains , Enfant , Herpèsvirus humain de type 3/immunologie , Herpèsvirus humain de type 3/physiologie , Mâle , Femelle , Interféron gamma/métabolisme , Enfant d'âge préscolaire , Adolescent , Transplantation de cellules souches hématopoïétiques , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Moelle osseuse , Cellules T mémoire/immunologie
2.
BMC Infect Dis ; 24(1): 691, 2024 Jul 11.
Article de Anglais | MEDLINE | ID: mdl-38992583

RÉSUMÉ

BACKGROUND: Hemorrhagic varicella (HV) is a particular form of chicken pox.,with high mortality in adults. This form of the disease is rare, to date, approximately 4 cases have been reported. Occasional cases of HV have been documented in adults with hematologic disorders or other diseases. While there is one reported case of simultaneous reactivation of cytomegalovirus in an adult with chickenpox, there is a lack of information regarding changes in liver function indicators for such patients. This is unfortunate, as CMV reactivation can further exacerbate liver failure and increase mortality. In this report, we present a case of hemorrhagic varicella reactivation with cytomegalovirus and provide some relevant discussions. CASE PRESENTATION: We present the case of a 25-year-old male with HV, who had a history of nephrotic syndrome generally controlled with orally administered prednisone at a dosage of 50 mg per day for two months. The patient arrived at the emergency room with complaints of abdominal pain and the presence of hemorrhagic vesicles on his body for the past 3 days. Despite medical evaluation, a clear diagnosis was not immediately determined. Upon admission, the leukocyte count was recorded as 20.96 × 109/L on the first day, leading to the initiation of broad-spectrum antibiotic treatment. Despite the general interpretation that a positive IgG and a negative IgM indicate a previous infection, the patient's extraordinarily elevated IgG levels, coupled with a markedly increased CMV DNA quantification, prompted us to suspect a reactivation of the CMV virus. In light of these findings, we opted for the intravenous administration of ganciclovir as part of the treatment strategy. Unfortunately,,the patient succumbed to rapidly worsening symptoms and passed away. Within one week of the patient's demise, chickenpox gradually developed in the medical staff who had been in contact with him. In such instances, we speculate that the patient's diagnosis should be classified as a rare case of hemorrhagic varicella. CONCLUSION: Swift identification and timely administration of suitable treatment for adult HV are imperative to enhance prognosis.


Sujet(s)
Varicelle , Co-infection , Infections à cytomégalovirus , Cytomegalovirus , Humains , Mâle , Adulte , Infections à cytomégalovirus/traitement médicamenteux , Infections à cytomégalovirus/complications , Infections à cytomégalovirus/virologie , Infections à cytomégalovirus/diagnostic , Cytomegalovirus/isolement et purification , Varicelle/traitement médicamenteux , Varicelle/complications , Varicelle/virologie , Varicelle/diagnostic , Co-infection/virologie , Co-infection/traitement médicamenteux , Antiviraux/usage thérapeutique , Antiviraux/administration et posologie , Hémorragie/virologie , Hémorragie/étiologie , Herpèsvirus humain de type 3/isolement et purification , Activation virale
4.
Wounds ; 36(6): 201-205, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-39018363

RÉSUMÉ

BACKGROUND: Purpura fulminans (PF) is a rare, life-threatening condition involving consumptive coagulopathy and intravascular thrombosis, causing purpura and necrosis in the skin and soft tissue. CASE REPORT: A 4-year-old Tajik girl with PF secondary to varicella-zoster virus (VZV) infection presented with purplish red, diffuse, painful lesions localized to the entire right leg. Her vaccination status was unknown, and she did not have concurrent chronic illness. Ten days before admission, the girl was admitted to another hospital in Tajikistan with a diagnosis of chickenpox and PF. She was then transferred to the hospital of the authors of the current report due to the enlargement of lesions to the gluteal region, a change in the color of lesions from red to black, and the detection of arterial thrombosis via Doppler ultrasonography. Multiple surgical debridements were performed to manage tissue necrosis, and the patient's right leg was amputated at the 18th week of admission. The patient was discharged after 26 weeks of hospitalization. CONCLUSION: Although VZV infections mostly cause mild and self-limiting eruptive disease, they can progress, with life-threatening complications, including PF. To prevent VZV infection and resulting complications, immunization with live attenuated vaccines and maintaining population immunity above a certain threshold are the most important strategies to prevent the circulation of the virus.


Sujet(s)
Purpura fulminans , Infection à virus varicelle-zona , Humains , Femelle , Purpura fulminans/virologie , Purpura fulminans/anatomopathologie , Enfant d'âge préscolaire , Infection à virus varicelle-zona/complications , Varicelle/complications , Débridement , Résultat thérapeutique , Amputation chirurgicale , Herpèsvirus humain de type 3
5.
Viruses ; 16(6)2024 May 24.
Article de Anglais | MEDLINE | ID: mdl-38932134

RÉSUMÉ

OBJECTIVE: This study aims to evaluate the safety and immunogenicity of the SKYVaricella vaccine in healthy Vietnamese children aged 12 months to 12 years. METHODS: This open-label, single-arm study involved 201 children divided into two groups: 60 children aged 12 months to 5 years and 141 children aged 6 to 12 years. Safety was assessed through immediate reactions, solicited adverse events within 7 days, and unsolicited events up to Day 42. Immunogenicity was evaluated by seroconversion rates (SCR) and geometric mean titer (GMT) increments using fluorescent antibody-to-membrane antigen (FAMA) on the day of vaccination (D0) and 42 days after vaccination (D42). RESULTS: All participants completed the follow-up. Immediate adverse events included pain (8.0%), redness (8.0%), and swelling (20.9%) at the injection site. Within 7 days, pain (17.9%) and swelling (12.4%) were mild and self-resolving. Unsolicited adverse events were infrequent and mild. Both age groups achieved 100% SCR. GMT of varicella-zoster virus antibodies increased from 1.37 (SD 1.97) at D0 to 18.02 (SD 2.22) at D42, a 13.12-fold rise. No Grade 3 adverse events were observed. CONCLUSION: The SKYVaricella vaccine shows a robust immunogenic response and favorable safety profile in Vietnamese children aged 12 months to 12 years. These findings endorse its potential inclusion in pediatric vaccination programs as a reliable preventive option against varicella.


Sujet(s)
Anticorps antiviraux , Vaccin contre la varicelle , Vaccins atténués , Humains , Mâle , Femelle , Vietnam , Enfant , Vaccin contre la varicelle/immunologie , Vaccin contre la varicelle/effets indésirables , Vaccin contre la varicelle/administration et posologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Nourrisson , Vaccins atténués/immunologie , Vaccins atténués/effets indésirables , Vaccins atténués/administration et posologie , Enfant d'âge préscolaire , Vaccination , Varicelle/prévention et contrôle , Varicelle/immunologie , Immunogénicité des vaccins , Herpèsvirus humain de type 3/immunologie , Peuples d'Asie du Sud-Est
6.
Nat Commun ; 15(1): 5318, 2024 Jun 22.
Article de Anglais | MEDLINE | ID: mdl-38909022

RÉSUMÉ

During primary varicella zoster virus (VZV) infection, infected lymphocytes drive primary viremia, causing systemic dissemination throughout the host, including the skin. This results in cytokine expression, including interferons (IFNs), which partly limit infection. VZV also spreads from skin keratinocytes to lymphocytes prior to secondary viremia. It is not clear how VZV achieves this while evading the cytokine response. Here, we show that VZV glycoprotein C (gC) binds IFN-γ and modifies its activity, increasing the expression of a subset of IFN-stimulated genes (ISGs), including intercellular adhesion molecule 1 (ICAM1), chemokines and immunomodulatory genes. The higher ICAM1 protein level at the plasma membrane of keratinocytes facilitates lymphocyte function-associated antigen 1-dependent T cell adhesion and expression of gC during infection increases VZV spread to peripheral blood mononuclear cells. This constitutes the discovery of a strategy to modulate IFN-γ activity, upregulating a subset of ISGs, promoting enhanced lymphocyte adhesion and virus spread.


Sujet(s)
Adhérence cellulaire , Herpèsvirus humain de type 3 , Molécule-1 d'adhérence intercellulaire , Interféron gamma , Kératinocytes , Lymphocytes T , Humains , Interféron gamma/métabolisme , Interféron gamma/immunologie , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Lymphocytes T/virologie , Molécule-1 d'adhérence intercellulaire/métabolisme , Molécule-1 d'adhérence intercellulaire/génétique , Kératinocytes/virologie , Kératinocytes/métabolisme , Kératinocytes/immunologie , Herpèsvirus humain de type 3/physiologie , Infection à virus varicelle-zona/immunologie , Infection à virus varicelle-zona/virologie , Agranulocytes/virologie , Agranulocytes/métabolisme , Agranulocytes/immunologie , Protéines de l'enveloppe virale/métabolisme , Antigène-1 associé à la fonction du lymphocyte/métabolisme
7.
Rev Med Virol ; 34(4): e2554, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38862398

RÉSUMÉ

The Varicella-zoster virus (VZV), classified as a neurotropic member of the Herpesviridae family, exhibits a characteristic pathogenicity, predominantly inducing varicella, commonly known as chickenpox, during the initial infectious phase, and triggering the reactivation of herpes zoster, more commonly recognized as shingles, following its emergence from a latent state. The pathogenesis of VZV-associated neuroinflammation involves a complex interplay between viral replication within sensory ganglia and immune-mediated responses that contribute to tissue damage and dysfunction. Upon primary infection, VZV gains access to sensory ganglia, establishing latent infection within neurons. During reactivation, the virus can spread along sensory nerves, triggering a cascade of inflammatory mediators, chemokines, and immune cell infiltration in the affected neural tissues. The role of both adaptive and innate immune reactions, including the contributions of T and B cells, macrophages, and dendritic cells, in orchestrating the immune-mediated damage in the central nervous system is elucidated. Furthermore, the aberrant activation of the natural defence mechanism, characterised by the dysregulated production of immunomodulatory proteins and chemokines, has been implicated in the pathogenesis of VZV-induced neurological disorders, such as encephalitis, myelitis, and vasculopathy. The intricate balance between protective and detrimental immune responses in the context of VZV infection emphasises the necessity for an exhaustive comprehension of the immunopathogenic mechanisms propelling neuroinflammatory processes. Despite the availability of vaccines and antiviral therapies, VZV-related neurological complications remain a significant concern, particularly in immunocompromised individuals and the elderly. Elucidating these mechanisms might facilitate the emergence of innovative immunomodulatory strategies and targeted therapies aimed at mitigating VZV-induced neuroinflammatory damage and improving clinical outcomes. This comprehensive understanding enhances our grasp of viral pathogenesis and holds promise for pioneering therapeutic strategies designed to mitigate the neurological ramifications of VZV infections.


Sujet(s)
Herpèsvirus humain de type 3 , Humains , Herpèsvirus humain de type 3/immunologie , Herpèsvirus humain de type 3/physiologie , Herpèsvirus humain de type 3/pathogénicité , Zona/virologie , Zona/immunologie , Infection à virus varicelle-zona/immunologie , Infection à virus varicelle-zona/virologie , Maladies du système nerveux/virologie , Maladies du système nerveux/immunologie , Maladies du système nerveux/étiologie , Animaux , Varicelle/virologie , Varicelle/immunologie , Maladies neuro-inflammatoires/immunologie , Maladies neuro-inflammatoires/virologie
8.
Pediatr Transplant ; 28(5): e14819, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38924278

RÉSUMÉ

BACKGROUND: Varicella-zoster virus (VZV) reactivation is the most common infectious complication in the late posthematopoietic stem cell transplantation (HSCT) period and is reported as 16%-41%. Acyclovir prophylaxis is recommended for at least 1 year after HSCT to prevent VZV infections. However, studies on the most appropriate prophylaxis are ongoing in pediatric patients. METHODS: Patients who underwent allogeneic HSCT between January 1, 1996 and January 1, 2020 were retrospectively analyzed to outline the characteristics of VZV reactivation after allogeneic HSCT in pediatric patients using 6 months acyclovir prophylaxis. RESULTS: There were 260 patients and 273 HSCTs. Median age was 10.43 (0.47-18.38), and 56% was male. Median follow-up was 2325 days (18-7579 days). VZV reactivation occurred in 21.2% (n = 58) at a median of 354 (55-3433) days post-HSCT. The peak incidence was 6-12 months post-HSCT (43.1%). Older age at HSCT, female gender, history of varicella infection, lack of varicella vaccination, low lymphocyte, CD4 count, and CD4/CD8 ratio at 9 and 12 months post-HSCT was found as a significant risk for herpes zoster (HZ) in univariate analysis, whereas history of varicella infection and low CD4/CD8 ratio at 12 months post-HSCT was an independent risk factor in multivariate analysis. CONCLUSIONS: Tailoring acyclovir prophylaxis according to pre-HCT varicella history, posttransplant CD4 T lymphocyte counts and functions, and ongoing immunosuppression may help to reduce HZ-related morbidity and mortality.


Sujet(s)
Aciclovir , Antiviraux , Transplantation de cellules souches hématopoïétiques , Herpèsvirus humain de type 3 , Activation virale , Humains , Aciclovir/usage thérapeutique , Mâle , Femelle , Enfant , Transplantation de cellules souches hématopoïétiques/effets indésirables , Études rétrospectives , Enfant d'âge préscolaire , Adolescent , Antiviraux/usage thérapeutique , Nourrisson , Activation virale/effets des médicaments et des substances chimiques , Herpèsvirus humain de type 3/immunologie , Zona/prévention et contrôle , Zona/étiologie , Infection à virus varicelle-zona/prévention et contrôle , Transplantation homologue , Facteurs de risque
9.
Front Immunol ; 15: 1408212, 2024.
Article de Anglais | MEDLINE | ID: mdl-38887303

RÉSUMÉ

Introduction: Varicella zoster virus (VZV) causes varicella and can reactivate as herpes zoster, and both diseases present a significant burden worldwide. However, the mechanisms by which VZV establishes latency in the sensory ganglia and disseminates to these sites remain unclear. Methods: We combined a single-cell sequencing approach and a well-established rhesus macaque experimental model using Simian varicella virus (SVV), which recapitulates the VZV infection in humans, to define the acute immune response to SVV in the lung as well as compare the transcriptome of infected and bystander lung-resident T cells and macrophages. Results and discussion: Our analysis showed a decrease in the frequency of alveolar macrophages concomitant with an increase in that of infiltrating macrophages expressing antiviral genes as well as proliferating T cells, effector CD8 T cells, and T cells expressing granzyme A (GZMA) shortly after infection. Moreover, infected T cells harbored higher numbers of viral transcripts compared to infected macrophages. Furthermore, genes associated with cellular metabolism (glycolysis and oxidative phosphorylation) showed differential expression in infected cells, suggesting adaptations to support viral replication. Overall, these data suggest that SVV infection remodels the transcriptome of bystander and infected lung-resident T cells and macrophages.


Sujet(s)
Poumon , Macaca mulatta , Animaux , Poumon/immunologie , Poumon/virologie , Macrophages alvéolaires/immunologie , Macrophages alvéolaires/virologie , Transcriptome , Lymphocytes T/immunologie , Varicellovirus/physiologie , Varicellovirus/immunologie , Macrophages/immunologie , Macrophages/virologie , Infections à Herpesviridae/immunologie , Infections à Herpesviridae/virologie , Herpèsvirus humain de type 3/immunologie , Herpèsvirus humain de type 3/physiologie , Modèles animaux de maladie humaine , Analyse sur cellule unique
10.
Rev Med Virol ; 34(4): e2556, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38853706

RÉSUMÉ

Stroke is a common worldwide cause of death and disability, resulting from an obstruction or reduction in blood flow to the brain. Research has demonstrated that systemic infection such as herpes zoster (HZ) / ophthalmicus herpes zoster (HZO) can potentially trigger stroke. This study includes an updated systematic review and meta-analysis of the epidemiologic data on the connection between HZ/HZO infection and the risk of stroke. A meticulous search of different database yielded 905 studies. Furthermore, an additional 14 studies from a previous meta-analysis were incorporated. Eligible studies underwent rigorous screening, resulting in 18 papers. Statistical analyses, including random/fixed effects models and subgroup analyses, were conducted to assess pooled relative risk (RR) and heterogeneity. The meta-analysis consisted of 5,505,885 participants and found a statistically significant association between HZ infection and the risk of stroke (pooled RR = 1.22, 95% confidence interval [CI] 1.12-1.34). The HZO infection showed a significantly higher overall pooled RR of 1.71 (95% CI 1.06-2.75), indicating a strong connection with the risk of stroke. Subgroup analysis revealed that the odds ratio might play a significant role in causing heterogeneity. Time since infection emerged as a crucial factor, with heightened stroke risk in the initial year post-HZ/HZO exposure, followed by a decline after the first year. Asian/Non-Asian studies demonstrated varied results in HZ/HZO patients. Meta-analysis reveals a significant HZ/HZO-stroke link. Subgroups highlight varied risks and warrant extended Asian/non-Asian patient investigation.


Sujet(s)
Zona , Accident vasculaire cérébral , Humains , Accident vasculaire cérébral/épidémiologie , Accident vasculaire cérébral/virologie , Zona/épidémiologie , Zona/virologie , Zona/complications , Appréciation des risques , Facteurs de risque , Herpèsvirus humain de type 3
11.
Nat Commun ; 15(1): 4932, 2024 Jun 10.
Article de Anglais | MEDLINE | ID: mdl-38858365

RÉSUMÉ

This study investigates the role of circular RNAs (circRNAs) in the context of Varicella-Zoster Virus (VZV) lytic infection. We employ two sequencing technologies, short-read sequencing and long-read sequencing, following RNase R treatment on VZV-infected neuroblastoma cells to identify and characterize both cellular and viral circRNAs. Our large scanning analysis identifies and subsequent experiments confirm 200 VZV circRNAs. Moreover, we discover numerous VZV latency-associated transcripts (VLTs)-like circRNAs (circVLTslytic), which contain multiple exons and different isoforms within the same back-splicing breakpoint. To understand the functional significance of these circVLTslytic, we utilize the Bacteria Artificial Chromosome system to disrupt the expression of viral circRNAs in genomic DNA location. We reveal that the sequence flanking circVLTs' 5' splice donor plays a pivotal role as a cis-acting element in the formation of circVLTslytic. The circVLTslytic is dispensable for VZV replication, but the mutation downstream of circVLTslytic exon 5 leads to increased acyclovir sensitivity in VZV infection models. This suggests that circVLTslytic may have a role in modulating the sensitivity to antiviral treatment. The findings shed new insight into the regulation of cellular and viral transcription during VZV lytic infection, emphasizing the intricate interplay between circRNAs and viral processes.


Sujet(s)
Herpèsvirus humain de type 3 , ARN circulaire , ARN viral , Réplication virale , ARN circulaire/génétique , ARN circulaire/métabolisme , Herpèsvirus humain de type 3/génétique , Humains , ARN viral/génétique , ARN viral/métabolisme , Réplication virale/génétique , Lignée cellulaire tumorale , Latence virale/génétique , Infection à virus varicelle-zona/virologie , Aciclovir/pharmacologie , Aciclovir/usage thérapeutique , Exons/génétique
14.
Epidemiol Infect ; 152: e81, 2024 May 13.
Article de Anglais | MEDLINE | ID: mdl-38736415

RÉSUMÉ

Nosocomial outbreak of varicella zoster virus (VZV) has been reported when susceptible individuals encounter a case of chicken pox or shingles. A suspected VZV outbreak was investigated in a 50-bedded in-patient facility of Physical Medicine and Rehabilitation in a tertiary care multispecialty hospital. A 30-year-old female patient admitted with Pott's spine was clinically diagnosed with chicken pox on 31 December 2022. The following week, four more cases were identified in the same ward. All cases were diagnosed as laboratory-confirmed varicella zoster infection by PCR. Primary case was a housekeeping staff who was clinically diagnosed with chicken pox 3 weeks prior (9 December 2022). He returned to work on eighth day of infection (17 December 2022) after apparent clinical recovery but before the lesions had crusted over. Thirty-one HCWs were identified as contacts a and three had no evidence of immunity. Two of these susceptible HCWs had onset of chickenpox shortly after first dose of VZV vaccination was inoculated. All cases recovered after treatment with no reported complications. VZV infection is highly contagious in healthcare settings with susceptible populations. Prompt identification of cases and implementation of infection prevention and control measures like patient isolation and vaccination are essential for the containment of outbreaks.


Sujet(s)
Infection croisée , Épidémies de maladies , Herpèsvirus humain de type 3 , Centres de soins tertiaires , Adulte , Humains , Varicelle/épidémiologie , Infection croisée/épidémiologie , Infection croisée/virologie , Herpèsvirus humain de type 3/isolement et purification , Inde/épidémiologie , Soins de longue durée , Infection à virus varicelle-zona/épidémiologie
15.
Vaccine ; 42(19): 4046-4055, 2024 Jul 25.
Article de Anglais | MEDLINE | ID: mdl-38762358

RÉSUMÉ

BACKGROUND: In South Korea, the National Immunization Program has included one-dose varicella vaccination for 1-year-olds since 2005. This study examines the potential impact of introducing a two-dose varicella vaccination for children, along with zoster vaccination for adults, using either the zoster vaccine live (ZVL) or recombinant zoster vaccine (RZV). METHODS: The investigation considered four strategies in a base case scenario. The first involved introducing zoster vaccination for 60-year-olds, with a 60 % coverage. The second strategy combined zoster vaccination with a second-dose varicella vaccination for 4-year-olds, with a 90 % coverage. An age-structured model spanning 50 years was employed, assuming a zoster vaccine catch-up campaign over the initial 5 years. Cost-effectiveness analyses were conducted, assessing incremental cost-effectiveness ratios (ICERs), incremental net monetary benefits (INMBs), and net loss under different ages at zoster vaccination (50, 60, 65, and 70 years) and varying willingness-to-pay (WTP) levels from ₩40 million ($34,998) to ₩84 million ($74,000). RESULTS: All strategies were cost-effective and significantly reduced herpes zoster (HZ) incidence, preventing approximately 3,077,000 to 7,609,000 cases, depending on the chosen strategy. The combined strategy prevented around 4,950,000 varicella and 653,000 HZ cases additionally. RZV outperformed ZVL by preventing twice as many HZ cases and offering greater QALY gains. However, ZVL was more cost-effective due to its lower cost. Probabilistic sensitivity analyses revealed that RZV became more cost-effective at higher WTP thresholds, exceeding ₩60.9 million ($53,193) in terms of ICER and ₩62.5 million ($54,591) for INMBs and net loss. The optimal age for zoster vaccination was 60 years concerning ICER but 50 years regarding INMB. CONCLUSIONS: Combining RZV with a two-dose varicella vaccination strategy reduced the disease burden and improved QALY more effectively, though ZVL remained more cost-effective at lower WTP levels. Decisions regarding vaccination policies should be balanced between the public health needs and WTP levels.


Sujet(s)
Vaccin contre la varicelle , Varicelle , Analyse coût-bénéfice , Vaccin contre le zona , Zona , Modèles théoriques , Vaccination , Humains , Zona/prévention et contrôle , Zona/épidémiologie , Zona/économie , République de Corée/épidémiologie , Varicelle/prévention et contrôle , Varicelle/épidémiologie , Varicelle/économie , Vaccin contre la varicelle/économie , Vaccin contre la varicelle/administration et posologie , Vaccin contre la varicelle/immunologie , Vaccin contre le zona/économie , Vaccin contre le zona/administration et posologie , Adulte d'âge moyen , Enfant d'âge préscolaire , Sujet âgé , Vaccination/économie , Vaccination/méthodes , Mâle , Femelle , Programmes de vaccination/économie , Enfant , Nourrisson , Adulte , Incidence , Herpèsvirus humain de type 3/immunologie
16.
J Clin Microbiol ; 62(6): e0010324, 2024 Jun 12.
Article de Anglais | MEDLINE | ID: mdl-38785446

RÉSUMÉ

The monkeypox virus (MPXV) outbreak, primarily endemic to Africa, has spread globally, with Brazil reporting the second-highest number of cases. The emergence of MPXV in non-endemic areas has raised concerns, particularly due to the co-circulation of other exanthematous viruses such as varicella-zoster virus (VZV) and molluscum contagiosum virus (MOCV). To perform an accurate differential diagnosis of MPXV during the ongoing outbreak in Minas Gerais, Brazil, a 5PLEX qPCR assay targeting orthopoxviruses (OPV), VZV, and MOCV was used to retrospectively analyze all clinical samples that tested negative for MPXV in the initial screening conducted at Funed. In summary, our study analyzed 1,175 clinical samples received from patients suspected of MPXV infection and found a positivity rate of 33.8% (397 samples) for MPXV using the non-variola qPCR assay. Testing the 778 MPXV-negative clinical samples using the 5PLEX qPCR assay revealed that 174 clinical samples (22.36%) tested positive for VZV. MOCV DNA was detected in 13 and other OPV in 3 clinical samples. The sequencing of randomly selected amplified clinical samples confirmed the initial molecular diagnosis. Analysis of patient profiles revealed a significant difference in the median age between groups testing positive for MPXV and VZV and a male predominance in MPXV cases. The geographic distribution of positive cases was concentrated in the most populous mesoregions of Minas Gerais state. This study highlights the challenges posed by emerging infectious diseases. It emphasizes the importance of epidemiological surveillance and accurate diagnosis in enabling timely responses for public health policies and appropriate medical care. IMPORTANCE: Brazil ranks second in the number of cases during the global monkeypox epidemic. The study, conducted in Minas Gerais, the second most populous state in Brazil with over 20 million inhabitants, utilized differential diagnostics, revealing a significant number of positive cases for other exanthematous viruses and emphasizing the need for accurate diagnoses. During the study, we were able to assess the co-circulation of other viruses alongside monkeypox, including varicella-zoster virus, molluscum contagiosum virus, and other orthopoxviruses. The significance of the research is underscored by the concentration of positive cases in populous areas, highlighting the challenges posed by emerging infectious diseases. This demographic context further amplifies the importance of the research in guiding public health policies and medical interventions, given the substantial population at risk. The study not only addresses a global concern but also holds critical implications for a state with such a large population and geographic expanse within Brazil. Overall, the study emphasizes the pivotal role of surveillance and precise diagnosis in guiding effective public health responses and ensuring appropriate medical interventions.


Sujet(s)
Épidémies de maladies , Humains , Brésil/épidémiologie , Études rétrospectives , Mâle , Femelle , Adulte , Diagnostic différentiel , Enfant , Adolescent , Orthopoxvirose simienne/diagnostic , Orthopoxvirose simienne/épidémiologie , Orthopoxvirose simienne/virologie , Jeune adulte , Enfant d'âge préscolaire , Adulte d'âge moyen , Virus de la variole simienne/génétique , Virus de la variole simienne/isolement et purification , Herpèsvirus humain de type 3/génétique , Herpèsvirus humain de type 3/isolement et purification , Nourrisson , Sujet âgé , Exanthème/virologie , Exanthème/épidémiologie , Réaction de polymérisation en chaine en temps réel
17.
Int Immunopharmacol ; 136: 112345, 2024 Jul 30.
Article de Anglais | MEDLINE | ID: mdl-38820959

RÉSUMÉ

The Ramsay-Hunt syndrome results from reactivation of the varicella-zoster virus at the geniculate ganglion level. The syndrome is characterized by a combination of symptoms such as ipsilateral facial paralysis, otalgia, and vesicles near the ear and auditory canal. The gold standard in the treatment of Ramsay-Hunt syndrome remains the combination of antiviral therapy with corticosteroids and adequate analgesic therapy. We present a case of a 45-year-old patient with severe form of atopic dermatitis, who developed this syndrome during treatment with dupilumab. The risks and benefits of dupilumab treatment in this patient were considered. Because both bronchial asthma and atopic dermatitis worsened when dupilumab was discontinued, it was indicated to continue this therapy with low-dose of acyclovir.


Sujet(s)
Anticorps monoclonaux humanisés , Eczéma atopique , Zona auriculaire , Humains , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux humanisés/effets indésirables , Adulte d'âge moyen , Eczéma atopique/traitement médicamenteux , Zona auriculaire/traitement médicamenteux , Zona auriculaire/diagnostic , Mâle , Antiviraux/usage thérapeutique , Antiviraux/effets indésirables , Herpèsvirus humain de type 3 , Aciclovir/usage thérapeutique , Asthme/traitement médicamenteux
18.
Arch Virol ; 169(5): 116, 2024 May 09.
Article de Anglais | MEDLINE | ID: mdl-38722402

RÉSUMÉ

In this study, we investigated the role of serum/glucocorticoid-regulated kinase 1 (SGK1) in varicella-zoster virus (VZV) replication. VZV DNA replication and plaque formation were inhibited by SGK1 knockout and treatment with an SGK1 inhibitor. Furthermore, SGK1 inhibition suppressed the increase in cyclin B1 expression induced by VZV infection. These results suggest that VZV infection induces SGK1 activation, which is required for efficient viral proliferation through the expression of cyclin B1. This is the first study to report that SGK1 is involved in the VZV life cycle.


Sujet(s)
Cycline B1 , Herpèsvirus humain de type 3 , Protéines précoces immédiates , Protein-Serine-Threonine Kinases , Réplication virale , Protéines précoces immédiates/génétique , Protéines précoces immédiates/métabolisme , Humains , Herpèsvirus humain de type 3/génétique , Herpèsvirus humain de type 3/physiologie , Protein-Serine-Threonine Kinases/génétique , Protein-Serine-Threonine Kinases/métabolisme , Cycline B1/métabolisme , Cycline B1/génétique , Lignée cellulaire , Réplication de l'ADN
19.
Int J Infect Dis ; 145: 107090, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38762045

RÉSUMÉ

OBJECTIVES: Encephalitis is a severe neurological syndrome for which herpesvirus and enteroviruses are the most common etiological agents. Arboviruses, a wildly diverse group of pathogens, are also critical epidemiological agents associated with encephalitis. In Brazil, little is known about the causative agents of encephalitis. METHODS: We conducted a hospital surveillance for encephalitis between 2020 and 2022. Molecular (RT-PCR and qPCR) and serological (virus-specific IgM and viral antigens) techniques were performed in cerebrospinal fluid and serum samples obtained from study participants. RESULTS: In the 43 participants evaluated, the etiologic agent or the presence of IgM was detected in 16 (37.2%). Nine (20.9%) cases were positive for chikungunya virus (CHIKV), three (7.0%) for dengue virus, two (4.7%) for human adenovirus, one (2.3%) for varicella-zoster virus, and one (2.3%) for enterovirus. Whole-genome sequencing revealed that the CHIKV identified belongs to the East/Central/South African lineage. CONCLUSION: Herein, CHIKV is a common pathogen identified in encephalitis cases. Our results reinforce previous evidence that chikungunya represents a significant cause of encephalitis during CHIKV outbreaks and epidemics and add to existing information on the epidemiology of encephalitis in Brazil.


Sujet(s)
Fièvre chikungunya , Virus du chikungunya , Humains , Brésil/épidémiologie , Virus du chikungunya/génétique , Virus du chikungunya/isolement et purification , Mâle , Femelle , Fièvre chikungunya/épidémiologie , Fièvre chikungunya/virologie , Fièvre chikungunya/diagnostic , Fièvre chikungunya/sang , Adulte , Adolescent , Enfant , Jeune adulte , Adulte d'âge moyen , Enfant d'âge préscolaire , Anticorps antiviraux/sang , Encéphalite virale/épidémiologie , Encéphalite virale/virologie , Encéphalite virale/diagnostic , Immunoglobuline M/sang , Sujet âgé , Virus de la dengue/génétique , Virus de la dengue/isolement et purification , Nourrisson , Phylogenèse , Herpèsvirus humain de type 3/génétique , Herpèsvirus humain de type 3/isolement et purification , Enterovirus/isolement et purification , Enterovirus/génétique , Séquençage du génome entier
20.
Virology ; 595: 110096, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38710129

RÉSUMÉ

Herpes stromal keratitis is the leading cause of infectious blindness in the western world. Infection by HSV1 is most common, but VZV and hCMV also infect the cornea. Multiple models of HSV1 corneal infection exist, but none for VZV and hCMV because of their host specificity. Here, we used commercially available 3D human corneal epithelial equivalents (HCEE) to study infection by these herpesviruses. HCEE was infected by HSV-1 and hCMV without requiring scarification and resulted in spreading infections. Spread of HSV-1 infection was rapid, while that of hCMV was slow. In contrast, infections with VZV required damage to the HCEE and did not spread. Acyclovir dramatically reduced replication of HSV-1 in this model. We conclude that highly quality-controlled, readily available HCEE is a useful model to study human-restricted herpesvirus infection of the human corneal epithelium and for screening of antiviral drugs for treating HSK in an 3D model system.


Sujet(s)
Antiviraux , Épithélium antérieur de la cornée , Herpèsvirus humain de type 1 , Kératite herpétique , Humains , Kératite herpétique/virologie , Kératite herpétique/traitement médicamenteux , Épithélium antérieur de la cornée/virologie , Épithélium antérieur de la cornée/anatomopathologie , Herpèsvirus humain de type 1/physiologie , Herpèsvirus humain de type 1/effets des médicaments et des substances chimiques , Antiviraux/pharmacologie , Antiviraux/usage thérapeutique , Herpèsvirus humain de type 3/physiologie , Herpèsvirus humain de type 3/effets des médicaments et des substances chimiques , Cytomegalovirus/physiologie , Cytomegalovirus/effets des médicaments et des substances chimiques , Réplication virale , Aciclovir/pharmacologie , Aciclovir/usage thérapeutique , Cellules épithéliales/virologie , Modèles biologiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...